Thursday, September 06, 2018 7:15:32 AM
http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNzUxMzF8Q2hpbGRJRD02OTk1NTQ=
The trial was designed several years ago when there was no FDA guidance.
Using current criteria (Dual threshold responder not required, just like MACI), how would Phase 3 NeoCart trial have done?
NeoCart would have demonstrated statistically significant results vs
microfracture on relevant IKDC & KOOS scales/endpoints at BOTH 1 year & 2 years
As I said yesterday, the market completely misread the numbers.
Microfracture patients performed significantly better than expected, and better than in most previous published studies (62% response vs. 50% projected in statistical plan) and real world experience. 1-year endpoint would have been statistically significant if two microfracture patients had not been responders. Clinicians in this trial requested current MCID analysis, which demonstrated superiority at 1 year
In > 2.2 cm lesions (MACI trial had mean lesion size of 4.8 !!!) : NeoCart 76% response rate vs 52% for microfracture (*p= 0.0145)
Failure Observations (% of patients at 1 year with scores below baseline)
– IKDC: 2.5% for NeoCart; 12.7% for microfracture
– KOOS: 3.7% for NeoCart; 3.7% for microfracture
– BOTH: 1.2% for NeoCart; 3.8% for microfracture
(Originally Posted on SA)
Recent OCGN News
- Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop • GlobeNewswire Inc. • 09/09/2024 10:30:12 AM
- Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit • GlobeNewswire Inc. • 09/05/2024 11:00:07 AM
- Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 09/03/2024 11:30:42 AM
- Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy • GlobeNewswire Inc. • 08/28/2024 10:30:32 AM
- Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication • GlobeNewswire Inc. • 08/26/2024 11:02:41 AM
- Ocugen, Inc. Investor Alert (NASDAQ: OCGN): Schubert Jonckheer & Kolbe LLP Investigating Potential Claims Against the Company's Officers and Directors Following Earnings Restatement and Possible Insider Trading • PR Newswire (US) • 08/20/2024 01:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/16/2024 08:16:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 12:00:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 05:03:56 PM
- Ocugen Provides Business Update with Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/08/2024 10:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 10:06:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 11:18:41 AM
- Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa • GlobeNewswire Inc. • 08/05/2024 10:30:33 AM
- Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock • GlobeNewswire Inc. • 08/02/2024 07:22:33 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/01/2024 01:18:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 01:16:00 PM
- Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock • GlobeNewswire Inc. • 08/01/2024 01:15:46 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/31/2024 08:16:21 PM
- Ocugen, Inc. Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 07/31/2024 08:15:04 PM
- Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 07/29/2024 11:02:15 AM
- Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy • GlobeNewswire Inc. • 07/25/2024 10:30:20 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 08:31:01 PM
- Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease • GlobeNewswire Inc. • 06/21/2024 11:00:00 AM
- Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication • GlobeNewswire Inc. • 06/20/2024 10:30:31 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/18/2024 08:29:04 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM